Financial Data and Key Metrics Changes - The company generated sales of $515 million for 2025, a decrease of 6% compared to $547 million in the prior year, slightly below the target range of $520 million-$535 million [16] - Adjusted EBITDA for 2025 was $39.2 million, slightly better than the previous year's $39.1 million [17] - Gross profit margin increased to 29% in 2025, while operating expenses as a percentage of sales decreased to 27% [17] Business Line Data and Key Metrics Changes - U.S. crop business sales were similar to the previous year, with improvements in herbicide sales, particularly with the product Xelo [16][26] - Specialty sales improved by 10%, driven by a joint development agreement and growth in mosquito vector solutions [17] - International operations saw a 14% decline in sales due to elevated channel inventories in Mexico and drought conditions in Australia [16] Market Data and Key Metrics Changes - The agricultural sector has not yet recovered from a downturn that began in 2023, with commodity prices remaining below historically normal levels [12] - Farmers are making more last-minute crop decisions, influenced by geopolitical issues, with a forecasted slight decrease in cotton and corn acreage, while soybean acreage is expected to increase [12][13] Company Strategy and Development Direction - The company is focused on improving its capital structure to pay down expiring credit facilities while maintaining financial flexibility for growth [4][5] - Rationalization of the Los Angeles manufacturing facility is expected to save at least $4 million annually, with production moving to the Axis, Alabama site [6][8] - The company aims to launch five new products in North America in 2026 and register at least 25 new products by 2031, with expectations of generating an additional $100 million in annual revenue from new products [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future performance, projecting adjusted EBITDA of $44 million-$48 million in 2026 on sales of $530 million-$550 million [14] - The company is confident in achieving a long-term EBITDA margin target of 15%, with a compound annual growth rate of 4%-6% expected [42][44] - Management acknowledged challenges in cash flow due to lower prepayments in Q4 but anticipates a favorable cash flow position in 2026 [33] Other Important Information - The company has remediated all material weaknesses identified during the 2024 audit, a significant achievement given the refinancing efforts [15] - Capital spending for 2025 was approximately $4 million, with expectations to increase in 2026 while remaining within the $5 million-$10 million range [19] Q&A Session Summary Question: What dragged on revenue and margin performance in Q4? - Management indicated that both international and domestic sales were affected, with lower metam sales and potato demand in the U.S. and drought conditions in Australia impacting international sales [25][26] Question: How do the L.A. closure and headquarters relocation fit into long-term transformation plans? - The rationalization of the L.A. facility and relocation of headquarters were not initially part of the transformation plan but became necessary as capacity utilization was analyzed [28][29] Question: Are there any cash proceeds associated with the closure of the Los Angeles facility? - There will be no immediate sale of the L.A. facility, which will continue to operate at a lower scale, but the headquarters relocation is expected to save $500,000 annually [30][32] Question: Is it possible to achieve free cash flow positive in 2026? - Management expressed confidence that adjusted EBITDA projections, less interest and capital expenditures, would lead to a favorable cash flow position in 2026 [33] Question: Can you provide more details on the $100 million expected from new products? - New products are primarily coming from insecticides and herbicides, with a mid-term definition extending to around 2030-2031 [37][40]

Financial Data and Key Metrics Changes - The company generated sales of $515 million for 2025, a decrease of 6% compared to $547 million in the prior year, slightly below the target range of $520 million-$535 million [16] - Adjusted EBITDA for 2025 was $39.2 million, slightly better than the previous year's $39.1 million [17] - Gross profit margin increased to 29% in 2025, while operating expenses as a percentage of sales decreased to 27% [17] Business Line Data and Key Metrics Changes - U.S. crop business sales were similar to the previous year, with improvements in herbicide sales, particularly with the Xelo product [16][26] - Specialty sales improved by 10%, driven by a joint development agreement and growth in mosquito vector solutions [17] Market Data and Key Metrics Changes - International sales were down 14% due to elevated channel inventories in Mexico and a persistent drought in Australia [16] - The agricultural economy has not yet recovered from a downturn that began in 2023, with farmers making more last-minute crop decisions [12] Company Strategy and Development Direction - The company is focused on rationalizing its manufacturing footprint, including the closure of the Los Angeles facility, which is expected to save at least $4 million annually [6][8] - A move to a smaller, more cost-effective headquarters in Irvine, California, is expected to save approximately $0.5 million annually [8] - The company aims to launch five new products in North America in 2026 and register at least 25 new products by 2031, with an estimated additional $100 million in annual revenue from new products [10][11] Management's Comments on Operating Environment and Future Outlook - Management noted that the worst of the industry destocking appears to be in the past, but distributors have not shown an inclination to restock inventories [12] - The company expects adjusted EBITDA of $44 million-$48 million in 2026 on sales of $530 million-$550 million, indicating optimism for improved performance [14] Other Important Information - The company has remediated all material weaknesses identified during the 2024 audit, a significant achievement [15] - The company plans to further decrease net working capital and improve operational efficiency through experienced supply chain leaders and modern management techniques [18] Q&A Session Summary Question: What dragged on revenue and margin performance? - Management indicated that both international and domestic sales were affected, with lower Metam sales and demand for potato products in the U.S. contributing to the shortfall [25][26] Question: How do the L.A. closure and headquarters relocation fit into long-term plans? - The rationalization of the L.A. facility and the move of headquarters were not part of the initial transformation plan but became necessary as capacity utilization was analyzed [28][29] Question: Are there any cash proceeds associated with the facility closures? - There will be no immediate sale of the L.A. facility, which will continue to operate at a lower scale, and the headquarters move is expected to save on lease costs [30][32] Question: Is it possible to achieve free cash flow positive in 2026? - Management expressed confidence that adjusted EBITDA projections, less interest and capital expenditures, should lead to a favorable cash flow position in 2026 [33] Question: Can you provide details on the $100 million from new products? - New products are primarily coming from insecticides and herbicides, with a mid-term definition extending to around 2030-2031 [37][40]

Financial Data and Key Metrics Changes - The company generated sales of $515 million for 2025, a decrease of 6% compared to $547 million in the prior year, slightly below the target range of $520 million-$535 million [16] - Adjusted EBITDA for 2025 was $39.2 million, slightly better than the previous year's $39.1 million, but below the target of $40-$44 million [8][17] - Gross profit margin increased to 29% in 2025, while operating expenses as a percentage of sales slightly decreased to 27% [17] Business Line Data and Key Metrics Changes - U.S. crop business sales were similar to the previous year, with improvements in herbicide sales, particularly for the Xelo product [16][25] - Specialty sales improved by 10%, driven by a joint development agreement and growth in mosquito vector solutions [17] - International operations saw a 14% decline in sales due to elevated channel inventories in Mexico and drought conditions in Australia [16] Market Data and Key Metrics Changes - The agricultural sector has not yet recovered from a downturn that began in 2023, with commodity prices remaining below historically normal levels [12] - Farmers are making more last-minute crop decisions, influenced by geopolitical issues, with a forecasted slight decrease in cotton and corn acreage, while soybean acreage is expected to increase [12] Company Strategy and Development Direction - The company is focused on improving its capital structure to pay down expiring credit facilities while maintaining financial flexibility for growth [4] - Plans include rationalizing the Los Angeles manufacturing facility, which is expected to save at least $4 million annually, and relocating the global headquarters to a more cost-effective space, saving approximately $500,000 annually [6][7] - The company aims to launch five new products in North America in 2026 and register at least 25 new products by 2031, with expectations of generating an additional $100 million in annual revenue from new products [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future performance, projecting adjusted EBITDA of $44 million-$48 million in 2026 on sales of $530 million-$550 million [14] - The company believes that future earnings power is substantially higher, allowing for debt repayment and investments in long-term growth [14] - Management acknowledged challenges in the agricultural economy but highlighted improvements in cost containment and operational efficiencies [18] Other Important Information - The company has remediated all material weaknesses identified during the 2024 audit, a significant achievement given the refinancing efforts [15] - Capital spending for 2025 was approximately $4 million, with expectations to increase spending in 2026 while remaining within the $5-$10 million range [19] Q&A Session Summary Question: What dragged on revenue and margin performance in Q4? - Management indicated that both international and domestic sales were affected, with lower Metam sales and demand for potato products in the U.S. and drought conditions in Australia impacting international sales [24][25] Question: How do the L.A. closure and headquarters relocation fit into long-term plans? - The rationalization of the L.A. facility and the headquarters move were not initially part of the transformation plan but became necessary as the company analyzed capacity utilization [27][28] Question: Are there any cash proceeds associated with the facility closures? - There are no immediate plans to sell assets from the L.A. facility, which will continue to operate at a lower scale, while the headquarters move is expected to save $500,000 annually [30][31] Question: Is it possible to achieve free cash flow positive in 2026? - Management expressed confidence that adjusted EBITDA projections, less interest and capital expenditures, would lead to a favorable cash flow position in 2026 [32] Question: Can you provide details on the $100 million revenue increase from new products? - New products are primarily coming from insecticides and herbicides, with a mid-term definition extending to around 2030-2031 [36][40]

Core Insights - The company faced a challenging macro environment in 2025, primarily due to U.S. tariff actions, which significantly impacted operations and customer behavior [5][6][12] - Despite these challenges, the company implemented strategic pricing increases and cost efficiency measures, leading to improved profitability and performance relative to peers [6][11][12] Financial Performance - Net income for 2025 was $18.2 million, or $0.83 per diluted share, compared to $8.9 million, or $0.41 per diluted share, in 2024 [18] - Adjusted EBITDA for the full year 2025 was $50.8 million, despite a 5% decline in net sales to $204.1 million [18][19] - The fourth quarter saw adjusted income from operations increase over 30% year-over-year, with adjusted net income of $23 million, or $1.05 per diluted share [12][18] Tariff Impact and Pricing Strategy - The implementation of 145% tariffs on goods sourced from China led to significant disruptions, including order cancellations [5][6] - The company was proactive in raising prices to offset tariff costs, which initially hurt volumes but ultimately restored pricing parity and improved margins [6][10][12] Cost Management - Selling, general, and administrative expenses decreased by 12% to $38 million in Q4, reflecting effective cost management strategies [11][21] - The company streamlined its infrastructure, resulting in lower distribution expenses as a percentage of goods shipped [21][49] International Segment Performance - International sales for the full year were $56.7 million, up 1.7% as reported, although down 17% on a constant currency basis [13] - The company gained market share in national accounts despite a decline in independent shops, indicating resilience in the international segment [13] Future Outlook - The company anticipates a return to more normal seasonality in 2026, with a focus on recovering sustainable top-line growth [16][27] - New product introductions, particularly in the Dolly brand, are expected to drive growth, with significant increases anticipated in 2026 [28][44] - The relocation of the East Coast distribution center is expected to enhance operational efficiency and support long-term growth initiatives [14][15]

Financial Data and Key Metrics Changes - Net sales for 2025 reached $2.13 billion, an increase of 6% year-over-year, driven by strong demand in the light-duty segment and successful tariff-related pricing initiatives [9][26] - Consolidated net sales for Q4 2025 were $538 million, up slightly from Q4 2024, but below internal expectations due to a larger customer adjusting their ordering patterns [11][23] - Adjusted diluted EPS for Q4 was $2.17, down 1% year-over-year, but at the high end of guidance [12][25] - Adjusted operating income was $93 million, flat compared to the previous year, with adjusted operating margin at 17.4%, slightly down year-over-year [24][25] Business Line Data and Key Metrics Changes - Light-duty business net sales in Q4 were $429 million, up slightly year-over-year, with POS at large customers estimated to be up mid-single digits [13][14] - Heavy-duty business net sales grew 6% year-over-year in Q4, with operating margin expanding by 130 basis points due to tariff timing [17][24] - Specialty vehicle segment saw flat top-line growth in Q4, with operating margin down year-over-year primarily due to increased wage and benefit expenses [19][20] Market Data and Key Metrics Changes - The light-duty market remains positive, with vehicle miles traveled increasing year-over-year and opportunities arising from OEM platform changes [15][16] - The heavy-duty segment faces pressure from the trucking and freight industry, with mixed signals making it difficult to predict a market rebound [18] - Specialty vehicle ridership remains strong, with no impact on overall end-user demand, although timing delays in purchases are noted [20][21] Company Strategy and Development Direction - The company emphasized innovation as a key priority, launching thousands of new SKUs and focusing on complex electronic solutions [5][6] - Operational excellence initiatives included deploying new automation technologies and diversifying the global sourcing footprint to reduce reliance on China [6][7] - The company aims for strategic growth through organic opportunities and is hopeful for increased M&A activity in the coming quarters [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the foundation built for continued growth and value creation, despite challenges from tariffs and market conditions [10][13] - The company expects total net sales growth of 7%-9% for 2026, with a focus on mid-single-digit POS growth and the impact of pricing initiatives [33][36] - Management acknowledged significant uncertainty regarding tariffs and global trade dynamics, which could affect future guidance [36][39] Other Important Information - The company ended 2025 with a strong balance sheet, net debt of $391 million, and total liquidity of $648 million [30] - A non-cash goodwill impairment charge of approximately $51 million was recorded in Q4, impacting GAAP results but adjusted out for EPS calculations [25] Q&A Session Summary Question: How is the light-duty business performing? - Management noted mid-single-digit POS growth, with a constructive environment for the aftermarket as vehicle age increases and miles driven rise [46][48] Question: Can you clarify the inventory growth and its relation to tariffs? - The majority of inventory growth is attributed to higher tariff costs, with some additional lift due to volume increases and pre-tariff purchases [57] Question: What gives confidence in the 7%-9% growth guidance? - Confidence stems from expected normalization of order patterns from a large customer and the anticipated impact of new product sales and pricing initiatives [66][68] Question: How will M&A be balanced with share repurchases? - The capital deployment strategy prioritizes debt management, organic growth investments, and opportunistic share repurchases, with expectations for increased M&A activity in 2026 [90][92]

Financial Data and Key Metrics Changes - For Q2 2026, net sales were $118.2 million, reflecting a 9% increase from $108.5 million in the prior year quarter, marking the ninth consecutive quarter of year-over-year sales growth [12] - GAAP operating income for the quarter was $9.0 million, or 7.6% of sales, compared to $11.7 million in the prior year quarter, which included a $5 million gain from the sale of a manufacturing facility [12][13] - The current quarter's operating income increased by 35% compared to adjusted operating income of $6.7 million or 6.1% of sales in the prior year quarter [13] Business Line Data and Key Metrics Changes - The increase in sales was primarily driven by higher unit volume in sourced soft seating products and pricing from tariff surcharges, partially offset by lower unit volume in made-to-order soft seating products and Homestyles branded ready-to-assemble products [12] - Sales order backlog at the end of the period was $82.4 million, which includes estimated tariff surcharges [12] Market Data and Key Metrics Changes - Industry demand remains uneven, with consumer behavior showing variability influenced by economic uncertainty and inflation concerns [8] - Feedback from retail partners indicates that consumer engagement fluctuates, impacting overall industry demand [8] Company Strategy and Development Direction - The company is focusing on agility, discipline, and long-term value creation, with a strong emphasis on new product introductions and strategic account growth [4][5] - Flexsteel is actively evaluating cost reduction opportunities and alternative supply chain options to strengthen its long-term position [10] Management's Comments on Operating Environment and Future Outlook - The management acknowledges that the U.S. economy shows resilience, but housing activity and discretionary spending remain inconsistent, weighing on overall industry demand [8] - The company expects some margin dilution in the second half of fiscal 2026 due to higher cost inventory burdened with tariffs, but remains confident in its ability to manage costs and protect margins [15][31] Other Important Information - The company ended the quarter with a cash balance of $36.8 million and working capital of $126 million, with no bank debt [14] - The increase in working capital was driven by higher cost inventory due to tariffs and an intentional increase in safety stock of top-selling products [15] Q&A Session Summary Question: Can you talk about unit volumes and pricing as far as how that impacted the quarter? - The tariff revenue in the quarter was approximately $9.5 million, with unit volumes relatively flat compared to the prior quarter, although some categories saw increases while others experienced declines [19][20] Question: What portion of your sales is now coming from new products? - Over the last 6-8 quarters, 30%-40% of overall sales have been derived from new products, which is a substantial driver for gaining market share [22] Question: Are there additional retailers that you think you may be underpenetrated in? - The company has identified about 20 large independent retailers as strategic accounts, with potential for significant growth through existing and emerging relationships [25][26] Question: How do you expect to offset tariff impacts going forward? - The company has been able to mitigate tariff impacts through pricing actions and cost savings initiatives, but expects some margin dilution in the back half of the year due to higher cost inventory [29][31] Question: Was there anything unusual regarding the tax rate this quarter? - There was a slight impact related to foreign taxes, but the tax rate going forward is expected to align more closely with the full-year tax rate [32]

Standex International (NYSE:SXI) Q2 2026 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsAdemir Sarcevic - CFOChristopher Howe - Head of Investor RelationsDavid Dunbar - CEOConference Call ParticipantsChris Moore - AnalystGary Prestopino - AnalystMatt Koranda - AnalystMike Shlisky - AnalystRoss Sparenblek - AnalystOperatorGood morning, ladies and gentlemen, and welcome to Standex International's Fiscal Second Quarter 2026 Financial Results Conference Call. At this time, all lines are in a lis ...

Summary of Merit Medical Systems FY Conference Call Company Overview - **Company Name**: Merit Medical Systems (NasdaqGS: MMSI) - **CEO**: Martha Aronson, appointed on October 3, 2025, succeeding founder Fred Lampropoulos [1][2] - **Market Cap**: Over $5 billion with revenues of $1.5 billion as of 2025 [3][4] - **Employee Count**: Over 7,500 employees globally [3] - **Global Footprint**: Vertically integrated manufacturing in Salt Lake City, Tijuana, Galway, and Singapore [3] Financial Performance - **Revenue Growth**: Total revenue increased at a 10% compounded annual growth rate (CAGR) over the last three years [4] - **Revenue Segmentation**: Approximately 40% of revenue from international customers and 60% from U.S. customers [4] - **Product Segmentation**: Revenue reported in two segments: cardiovascular and endoscopy [4] - **Foundational Products**: Comprise about two-thirds of revenue with a 6% CAGR over the last three years [5] - **Therapeutic Products**: Comprise about one-third of revenue with a 19% CAGR over the last three years [5] Strategic Initiatives - **Mergers and Acquisitions**: Over $1 billion invested in M&A since 2016, crucial for growth [3] - **Continued Growth Initiatives (CGI)**: Targeting a 5%-7% CAGR in revenue, 20%-22% non-GAAP operating margin, and over $400 million in cumulative free cash flow from FY23 to FY26 [15][14] - **Recent Performance**: Preliminary revenue for 2025 projected at $1.5 billion, up 11% [15] Product Development and Innovation - **Cardiac Therapies**: One of the fastest-growing segments with mid-teens growth; includes lead extraction technology from Cook Medical [8] - **Endoscopy Portfolio**: Focus on GERD treatment and tumor localization for breast cancer with the Scout system [9][10] - **Renal Therapies**: Includes dialysis products and the WRAPSODY endoprosthesis for dialysis patients [10][11] Market Position and Competitive Strategy - **Customer Focus**: Emphasis on being a customer-focused organization, leveraging both organic and inorganic growth strategies [29] - **Acquisition Strategy**: Active in pursuing small tuck-in acquisitions to fill strategic gaps, with a disciplined financial approach [36][37] - **Global Market Strategy**: Direct sales combined with distributor partnerships in international markets [12] Challenges and Considerations - **Tariffs Impact**: Anticipated impact of $13-$15 million from tariffs in 2026 [23] - **OEM Business**: Experienced softness due to a slowdown in the coatings business in China [21] - **Reimbursement Issues**: WRAPSODY faced challenges with reimbursement approvals, but the company is pivoting its pricing strategy [30] Leadership Transition - **Board Changes**: Fred Lampropoulos resigned as chairman; F. Ann Millner appointed as new chairman [22] - **Leadership Confidence**: The transition is seen as smooth, with confidence in the internal team's readiness to continue the company's momentum [22] Future Outlook - **Focus on Growth**: Continued emphasis on scaling the business globally while reinforcing existing infrastructure [28] - **Long-term Planning**: Strategy development for 2027-2030 to be informed by current growth platforms [18] - **Investment in R&D**: Plans to prioritize R&D efforts based on customer needs and market opportunities [18][46] This summary encapsulates the key points from the conference call, highlighting Merit Medical's financial performance, strategic initiatives, product development, market positioning, challenges, and future outlook.

Teva Pharmaceutical Industries Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Event**: 2025 Conference at BofA Healthcare Conference - **Date**: September 24, 2025 Key Points Capital Allocation and Business Strategy - Teva is focused on capital allocation, emphasizing net debt paydown while also investing in innovative products [1][2] - The innovative segment of Teva's portfolio has grown significantly, with a 27% increase in the last year, contrasting with a 2% decline in the generics business [3][4] - Teva aims to streamline its generics pipeline, focusing on 65% of drugs coming off patent, which covers the majority of value [4][5] - The company is targeting operational efficiency, aiming to reduce costs by $700 million to support innovation [4][5] - Teva is exploring opportunities in China for acquiring de-risked assets, indicating a flexible R&D approach [9][10] Product Pipeline and Growth Drivers - Teva anticipates significant growth from products like Austedo, projected to peak at $3 billion, and Ajovy, expected to reach $1.5 to $2 billion [3][6] - The launch of olanzapine is expected to be a major growth driver, with a focus on maintaining pricing integrity rather than discounting for market access [6][33] - Teva's innovative business is expected to offset losses from the generic Revlimid, with a strong emphasis on cost efficiency [32][33] Cost of Goods and Operational Efficiency - Teva has committed to saving $700 million by 2027, with two-thirds of that expected by the end of 2026, focusing on improving cost of goods sold (COGS) [27][28] - The company is implementing a COGS improvement program, which is expected to yield results primarily in 2027 [28][30] - Teva is enhancing operational efficiency by increasing the number of efficiency programs from six to fourteen [29] Market Dynamics and Competitive Landscape - The market for Austedo is characterized as a growth category, with a focus on patient adherence and compliance programs [37][41] - Teva is positioned as a leading psychiatric company, leveraging its credibility and existing relationships with healthcare providers [44][62] - The company is optimistic about the potential for Darii, a new product, to capture market share by targeting pediatric patients and those struggling with existing devices [72][74] Regulatory and Market Challenges - Teva is preparing for the impact of the Inflation Reduction Act (IRA) and is committed to providing clarity to investors regarding its implications [51][55] - The company is insulated from European tariffs due to its innovative portfolio, particularly with products like Austedo manufactured in the U.S. [81][83] Future Outlook - Teva is optimistic about its long-term growth trajectory, with a focus on launching new products and maintaining a robust pipeline [49][50] - The company is planning for sustained revenue growth through innovative products, with a unique position in the market that allows for continuous product launches [49][68] Additional Insights - Teva's approach to R&D is characterized by a "small R, big D" philosophy, indicating a focus on development rather than extensive in-house research [9][10] - The company is committed to maintaining a disciplined approach to capital allocation, ensuring that new acquisitions align with its strategic goals [5][10] - Teva's leadership emphasizes the importance of maintaining gross margins while navigating the complexities of the pharmaceutical market [30][67]

Core Insights - Butler National Corporation reported a strong financial performance for the first quarter of fiscal 2026, with operating income rising by 32% and earnings per share increasing from $0.03 to $0.06 [1][3] Financial Performance - Revenue for the first quarter of fiscal 2026 was $20.125 million, a 1.5% increase from $19.828 million in the same period of fiscal 2025 [2] - Operating income increased to $4.667 million from $3.536 million, marking a 32% rise [2] - Net income rose by 64% to $3.685 million compared to $2.246 million in the prior year [2][3] - Total assets increased to $130.283 million from $112.298 million [2] Business Segment Performance Aerospace Products - Revenue in the Aerospace Products segment increased by 7% to $11.3 million, driven by a $1.2 million increase in Special Missions Electronics and a $1.0 million increase in Aircraft Avionics [9] - Costs decreased by 12% to $6.6 million, resulting in an operating margin of 25% compared to 13% in the same quarter of the previous year [9] Professional Services - Revenue from Professional Services decreased by 5% to $8.8 million, with mobile sports wagering revenue increasing to $1.3 million [10] - Traditional casino gaming revenue saw a decline of $0.6 million compared to the same quarter last year [10] Management Commentary - The CEO highlighted the strong start to fiscal 2026, attributing revenue growth to efficiencies in production and increased deliveries in the Aerospace Products segment [3] - The company invested approximately $0.6 million in the development of new products, leading to additional FAA Supplemental Type Certificate approvals [5][6] Share Repurchase - The company repurchased 2.41 million shares during the first quarter, demonstrating a commitment to maximizing stockholder value [8]